Skip to main navigation Skip to search Skip to main content

Predictors of response to ziprasidone: Results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state

  • C. U. Pae
  • , A. A. Patkar
  • , W. Gilmer
  • , N. Holtzman
  • , S. B. Thommi
  • , S. N. Ghaemi
  • Duke University
  • Northwestern University
  • Tufts Medical Center
  • Tufts University

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Introduction: The present study is aimed at investigating possible predictors of response to ziprasidone in a sample of patients with mixed depressive state. Methods: 72 patients were randomized to either ziprasidone or placebo and treated prospectively for 6 weeks. The clinical response and remission were defined with various clinical variables including Montgomery Asberg Depression Rating Scale. Further outcome measures included predictors of remission and other clinical variables over time. Results: None of the variables under investigation were significantly associated with response or remission at 6 weeks (all p-values>0.003, respectively). Conclusion: Further investigations are warranted due to clear limitations, mostly small sample size and use of concomitant medications.

Original languageEnglish
Pages (from-to)152-155
Number of pages4
JournalPharmacopsychiatry
Volume45
Issue number4
DOIs
StatePublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • bipolar disorder
  • clinical trial
  • mixed depressive episode
  • predictor to response
  • ziprasidone

Fingerprint

Dive into the research topics of 'Predictors of response to ziprasidone: Results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state'. Together they form a unique fingerprint.

Cite this